A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer

Melissa A. Geller, Joseph J. Ivy, Rahel Ghebre, Levi S. Downs, Patricia L. Judson, Linda F. Carson, Amy L. Jonson, Kathryn Dusenbery, Rachel Isaksson Vogel, Matthew P. Boente, Peter A. Argenta

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

Original languageEnglish (US)
Pages (from-to)112-117
Number of pages6
JournalGynecologic oncology
Volume121
Issue number1
DOIs
StatePublished - Apr 1 2011

Fingerprint

docetaxel
Carboplatin
Endometrial Neoplasms
Radiotherapy
Disease-Free Survival
Kaplan-Meier Estimate
Survival
Consolidation Chemotherapy
Confidence Intervals
Drug Therapy
Brachytherapy
Area Under Curve
Cell Biology
Histology
Appointments and Schedules
Therapeutics
Radiation
Biopsy

Keywords

  • Advanced stage
  • Chemotherapy
  • Endometrial cancer
  • Radiation

Cite this

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. / Geller, Melissa A.; Ivy, Joseph J.; Ghebre, Rahel; Downs, Levi S.; Judson, Patricia L.; Carson, Linda F.; Jonson, Amy L.; Dusenbery, Kathryn; Vogel, Rachel Isaksson; Boente, Matthew P.; Argenta, Peter A.

In: Gynecologic oncology, Vol. 121, No. 1, 01.04.2011, p. 112-117.

Research output: Contribution to journalArticle

@article{d229fafe711844a9af03a7fc43129d49,
title = "A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a {"}Sandwich{"} method for stage III, IV, and recurrent endometrial cancer",
abstract = "Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95{\%} (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78{\%} (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95{\%} confidence intervals for OS at 1 year were 95{\%} (82-99{\%}), at 3 years 90{\%} (75-96{\%}), and at 5 years 71{\%} (45-86{\%}). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95{\%} confidence intervals for PFS at 1 year were 87{\%} (72-94{\%}), at 3 years 71{\%} (51-83{\%}), and at 5 years 64{\%} (42-80{\%}). Conclusions: {"}Sandwiching{"} radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.",
keywords = "Advanced stage, Chemotherapy, Endometrial cancer, Radiation",
author = "Geller, {Melissa A.} and Ivy, {Joseph J.} and Rahel Ghebre and Downs, {Levi S.} and Judson, {Patricia L.} and Carson, {Linda F.} and Jonson, {Amy L.} and Kathryn Dusenbery and Vogel, {Rachel Isaksson} and Boente, {Matthew P.} and Argenta, {Peter A.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.ygyno.2010.12.338",
language = "English (US)",
volume = "121",
pages = "112--117",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer

AU - Geller, Melissa A.

AU - Ivy, Joseph J.

AU - Ghebre, Rahel

AU - Downs, Levi S.

AU - Judson, Patricia L.

AU - Carson, Linda F.

AU - Jonson, Amy L.

AU - Dusenbery, Kathryn

AU - Vogel, Rachel Isaksson

AU - Boente, Matthew P.

AU - Argenta, Peter A.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

AB - Objective: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%). Conclusions: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

KW - Advanced stage

KW - Chemotherapy

KW - Endometrial cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=79952817755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952817755&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.12.338

DO - 10.1016/j.ygyno.2010.12.338

M3 - Article

C2 - 21239048

AN - SCOPUS:79952817755

VL - 121

SP - 112

EP - 117

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -